Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.

Citation data:

Best practice & research. Clinical obstetrics & gynaecology, ISSN: 1532-1932, Vol: 41, Page: 126-138

Publication Year:
2017
Usage 19
Abstract Views 14
Link-outs 5
Captures 14
Readers 14
Social Media 5
Shares, Likes & Comments 5
Citations 7
Citation Indexes 7
PMID:
28027849
DOI:
10.1016/j.bpobgyn.2016.11.004
Author(s):
Webber, Kate; Friedlander, Michael
Publisher(s):
Elsevier BV
Tags:
Medicine
review description
Chemotherapy plays a key role in the management of women with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC). Platinum- and taxane-based regimens are the standard of care for adjuvant treatment in early-stage EOC and first-line therapy for advanced stage disease. Efforts to define the optimal scheduling, timing and route of administration are ongoing. The majority of women with EOC will develop recurrent disease, and treatment options for these women are depend on the time that has elapsed from first-line therapy. Platinum-based doublet chemotherapy is preferred for women with platinum-sensitive recurrent cancer. In platinum-resistant relapsed EOC, options are much more limited, and careful consideration of symptoms, performance status, anticipated toxicity and quality of life is essential when recommending chemotherapy for these women.